Odonate Therapeutics – Consensus Indicates Potential 20.5% Upside

Broker Ratings

Odonate Therapeutics with ticker code (ODT) now have 3 analysts covering the stock with the consensus suggesting a rating of ‘Hold’. The target price ranges between 4 and 4 calculating the average target price we see 4. Now with the previous closing price of 3.32 this is indicating there is a potential upside of 20.5%. There is a 50 day moving average of 8.71 and the 200 day moving average is 15.76. The company has a market cap of $132m. Company Website: http://www.odonate.com

Odonate Therapeutics, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index